P2RY2 (Purinergic Receptor P2Y2)

P2RY2 (Purinergic Receptor P2Y2)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">p2ry2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>P2RY2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Purinergic Receptor P2Y2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11</td>
</tr>
<tr>
<td class="label">Genomic Location</td>
<td>11q13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5029</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>173415</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000165326</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9ULL8</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>P2Y receptor family (GPCR)</td>
</tr>
<tr>
<td class="label">Protein Product</td>
<td>P2Y2 receptor, 43 kDa</td>
</tr>
<tr>
<td class="label">Agonist</td>
<td>EC50</td>
</tr>
<tr>
<td class="label">ATP</td>
<td>~1 μM</td>
</tr>
<tr>
<td class="label">UTP</td>
<td>~1 μM</td>
</tr>
<tr>
<td class="label">2-MeSATP</td>
<td>~0.1 μM</td>
</tr>
<tr>
<td class="label">Ap4A</td>
<td>~1 μM</td>
</tr>
<tr>
<td class="label">Antagonist</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">Suramin</td>
<td>~100 μM</td>
</tr>
<tr>
<td class="label">PPADS</td>
<td>~50 μM</td>
</tr>
<tr>
<td class="label">Diquafosol</td>
<td>~10 μM</td>
</tr>
<tr>

P2RY2 (Purinergic Receptor P2Y2)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">p2ry2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>P2RY2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Purinergic Receptor P2Y2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11</td>
</tr>
<tr>
<td class="label">Genomic Location</td>
<td>11q13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5029</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>173415</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000165326</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9ULL8</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>P2Y receptor family (GPCR)</td>
</tr>
<tr>
<td class="label">Protein Product</td>
<td>P2Y2 receptor, 43 kDa</td>
</tr>
<tr>
<td class="label">Agonist</td>
<td>EC50</td>
</tr>
<tr>
<td class="label">ATP</td>
<td>~1 μM</td>
</tr>
<tr>
<td class="label">UTP</td>
<td>~1 μM</td>
</tr>
<tr>
<td class="label">2-MeSATP</td>
<td>~0.1 μM</td>
</tr>
<tr>
<td class="label">Ap4A</td>
<td>~1 μM</td>
</tr>
<tr>
<td class="label">Antagonist</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">Suramin</td>
<td>~100 μM</td>
</tr>
<tr>
<td class="label">PPADS</td>
<td>~50 μM</td>
</tr>
<tr>
<td class="label">Diquafosol</td>
<td>~10 μM</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Diquafosol</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">INS37217</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Suramin</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">AR-C118925</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Milestone</td>
</tr>
<tr>
<td class="label">1995</td>
<td>P2Y2 cloning</td>
</tr>
<tr>
<td class="label">2000</td>
<td>Dual ATP/UTP recognition</td>
</tr>
<tr>
<td class="label">2006</td>
<td>CNS expression characterized</td>
</tr>
<tr>
<td class="label">2013</td>
<td>Neuroinflammation link</td>
</tr>
<tr>
<td class="label">2017</td>
<td>AD research</td>
</tr>
<tr>
<td class="label">2019</td>
<td>Therapeutic targeting</td>
</tr>
<tr>
<td class="label">2021</td>
<td>PD models</td>
</tr>
<tr>
<td class="label">2023</td>
<td>Novel therapeutics</td>
</tr>
<tr>
<td class="label">Species</td>
<td>ATP Sensitivity</td>
</tr>
<tr>
<td class="label">Human</td>
<td>High</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Similar</td>
</tr>
<tr>
<td class="label">Rat</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Non-human primate</td>
<td>Similar to human</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">31 edges</a></td>
</tr>
</table>

Introduction

The P2RY2 gene encodes the P2Y2 receptor, a G protein-coupled receptor (GPCR) that responds to both adenine and uridine nucleotides, particularly ATP and UTP. P2Y2 is a unique member of the P2Y receptor family because it is activated by both ATP and UTP with similar potency, making it a central sensor of cellular stress and tissue damage. Beyond its well-characterized roles in airway and mucosal immunity, P2Y2 is increasingly recognized as an important mediator of neuroinflammation and neurodegenerative disease pathogenesis in Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders. [@burnstock1999]

P2Y2 is widely expressed throughout the central nervous system (CNS), with high levels in microglia, astrocytes, and neurons. The receptor signals through Gq proteins, activating phospholipase C (PLC) and leading to intracellular calcium mobilization, similar to P2Y1. However, P2Y2 also couples to Gi proteins in certain cell types, providing additional signaling complexity. The dual nucleotide specificity of P2Y2 makes it a critical sensor of cellular damage, as both ATP and UTP are released from damaged or stressed cells. [@chen2006]

Gene Overview

Gene Structure and Regulation

Genomic Architecture

The P2RY2 gene is located on chromosome 11q13.2 and consists of 2 exons spanning approximately 3.2 kilobases. The gene structure is conserved across mammals, though alternative splicing generates multiple transcript variants in some species.

Transcriptional Regulation

P2RY2 expression is dynamically regulated:

Protein Structure and Function

Structural Features

The P2Y2 receptor is a typical class A GPCR with seven transmembrane domains:

Unique Ligand Specificity

P2Y2 is unique among P2Y receptors in responding to both purine and pyrimidine nucleotides:

Signaling Pathways

P2Y2 couples to multiple G proteins:

Normal Function in the Brain

Cellular Expression

P2Y2 receptors are expressed in multiple CNS cell types:

Physiological Roles

ATP and UTP Release

Understanding nucleotide release is key to P2Y2 function:

Role in Alzheimer's Disease

Evidence for P2Y2 Involvement

P2Y2 receptors are implicated in AD pathogenesis through multiple mechanisms:

Mechanisms of Contribution

• Cytokine and chemokine production
• Microglial activation and morphologic changes
• Oxidative stress generation

• Excitotoxicity
• Mitochondrial dysfunction
• Apoptotic pathways

Therapeutic Implications

P2Y2 targeting in AD:

• Antagonists: May reduce neuroinflammation
• Agonists: May promote neuroprotection through different mechanisms
• Dual considerations: Cell-type specific effects matter
• Challenges: Understanding timing and context

Role in Parkinson's Disease

Evidence for P2Y2 Involvement

P2Y2 contributes to PD through:

Mechanisms

• Pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
• Oxidative stress through NADPH oxidase activation
• Nitric oxide production

• Calcium dysregulation
• Energy failure
• Apoptosis

Experimental Models

• MPTP model: P2Y2 modulates dopaminergic neuron loss
• α-Synuclein models: P2Y2 affects pathology progression
• In vitro: P2Y2 activation promotes neurotoxicity

Role in Neuroinflammation

Microglial Activation

P2Y2 is a key regulator of microglial responses:

Signaling Pathways

Cross-talk

P2Y2 interacts with multiple signaling pathways:

Role in Neurovascular Function

Blood-Brain Barrier

P2Y2 influences BBB function:

Stroke and Ischemia

P2Y2 in cerebral ischemia:

Therapeutic Targeting

Drug Development

Challenges

Novel Approaches

Molecular Interactions

Protein Interactions

Signaling Network

Genetic Associations

P2RY2 Polymorphisms

• rs2854237: Associated with inflammatory disease
• rs1714719: Modified asthma risk
• rs4385544: Potential disease associations
• Population-specific variants may influence susceptibility

Research Timeline

Key Publications

Animal Models

Genetic Models

• P2Y2 knockout mice: Viable with mucosal and immune phenotypes
• Conditional knockout: Tissue-specific deletion
• Humanized models: Improved translation

Disease Models

• APP/PS1 mice: P2Y2 modulates pathology
• MPTP model: P2Y2 affects dopaminergic neuron loss
• Ischemia model: P2Y2 blockade provides neuroprotection

Conclusions

The P2RY2 gene encodes a unique purinergic receptor that responds to both ATP and UTP, making it a central sensor of cellular stress and tissue damage in the CNS. P2Y2 plays complex roles in neuroinflammation and neurodegenerative disease, with contributions to microglial activation, cytokine production, and neuronal dysfunction in AD and PD. Therapeutic targeting of P2Y2 faces challenges related to BBB penetration and the dual nature of receptor signaling (pro-inflammatory vs. protective). Understanding the cell-type-specific and context-dependent functions of P2Y2 will be critical for developing effective neuroprotective strategies. The development of brain-penetrant selective agonists and antagonists, along with biomarker-driven patient selection, represents a promising avenue for translating P2Y2 research into disease-modifying therapies for neurodegenerative conditions.

Brain Region Expression

Hippocampus

The hippocampus shows dynamic P2Y2 expression:

Functions:

• Memory formation and consolidation
• Spatial navigation
• Injury response mechanisms
• Seizure modulation

Cortex

Cortical P2Y2 distribution:

Roles:

• Sensory integration
• Motor coordination
• Cognitive processing
• Corticothalamic feedback

Substantia Nigra

P2Y2 in basal ganglia:

Clinical significance:

• Parkinson's disease vulnerability
• Dopaminergic neuron survival
• Movement control
• Therapeutic targeting

White Matter

P2Y2 in white matter tracts:

Functions:

• Oligodendrocyte function
• Myelin maintenance
• Axonal health
• Injury responses

Cell Type-Specific Functions

Microglial P2Y2

Microglia show highest P2Y2 expression:

Activation states:

• Resting/surveiling microglia
• Primed microglia
• Activated/reactive microglia
• Dystrophic/age-associated microglia

• Cytokine production (IL-1β, TNF-α, IL-6)
• Chemokine release
• Phagocytosis modulation
• ROS/RNS generation
• Neurotoxicity vs. neuroprotection

Neuronal P2Y2

Neuronal P2Y2 functions:

Synaptic activity:

• Presynaptic neurotransmitter release
• Postsynaptic response modulation
• Activity-dependent plasticity

• Metabolic regulation
• Calcium homeostasis
• Survival signaling
• Axonal protection

Astrocytic P2Y2

Astrocyte P2Y2 roles:

Homeostatic functions:

• Potassium buffering
• Water balance
• Metabolic support
• Ion homeostasis

• Glial scar formation
• Injury containment
• Inflammation modulation
• Tissue repair

Disease Mechanisms in AD

Amyloid Cascade Interaction

P2Y2 intersects with Aβ pathology:

Tau Pathology Connection

P2Y2 and tau:

Therapeutic Targeting in AD

Current approaches:

• Antagonists: Reduce neuroinflammation
• Agonists: May promote neuroprotection
• Gene therapy: Modulate expression
• Combination: Multi-target strategies

Disease Mechanisms in PD

Dopaminergic Vulnerability

P2Y2 in substantia nigra:

α-Synuclein Interactions

P2Y2 and α-Syn:

Therapeutic Strategies

Targeting P2Y2 in PD:

• Neuroprotection: Preventing neuron loss
• Anti-inflammatory: Reducing microglial activation
• Disease modification: Slowing progression
• Biomarker development: Patient selection

Aging and Neurodegeneration

Age-Related Expression Changes

Aging affects P2Y2:

Intervention Strategies

Modulating aging effects:

Comparative Pharmacology

Species Differences

P2Y2 pharmacology shows species variation:

Translation Implications

Species differences affect:

• Preclinical to clinical translation
• Dose selection
• Efficacy predictions
• Safety assessments

Drug Development Pipeline

Clinical Candidates

Current development status:

• Phase I: First-in-human studies beginning
• Preclinical: Multiple compounds in development
• Research: Novel chemical entities
• Repurposing: Existing drugs with new indications

Novel Delivery Methods

Emerging approaches:

Regulatory Status

Current Approvals

P2Y2-related drugs:

• Diquafosol: Approved for dry eye (topical)
• Other agonists: Research stage
• Antagonists: Preclinical/clinical

Development Challenges

• BBB penetration: Primary obstacle
• Safety profile: Chronic dosing concerns
• Efficacy: Demonstrating disease modification
• Biomarkers: Patient selection needs

Research Gaps

Unmet Needs

Future Directions

• Structural studies: Guide drug design
• Cell-type specific functions: Targeted approaches
• Biomarker qualification: Precision medicine
• Gene therapy: Novel modalities

Additional Clinical Considerations

Patient Stratification

Safety Monitoring

Clinical Trial Design

See Also

• [P2RY1 Gene](/genes/p2ry1)
• [P2RY12 Gene](/genes/p2ry12)
• [P2RX7 Gene](/genes/p2rx7)
• [Purinergic Signaling](/mechanisms/purinergic-signaling)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Microglia](/cell-types/microglia)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neurovascular Unit](/mechanisms/neurovascular-unit)

Pathway Diagram

The following diagram shows the key molecular relationships involving P2RY2 (Purinergic Receptor P2Y2) discovered through SciDEX knowledge graph analysis: